DRUG — BRIGHT MINDS BIOSCIENCES INC.
Price · 2024-08-26 → 2026-08-21
499 daily closes shownAnonymous view is capped at two years of history. A free account extends it to five, and Pro opens the whole archive back to 2021-11-08.
Performance
Technicals
Measured signals that fired on DRUG
| date | signal | measured base rate |
|---|---|---|
| 2026-08-21 | Fair value gap, bearish structure | -0.45% over 21 days · t = -3.29 · n = 108,591 statistically distinguishable from its control group |
| 2026-08-19 | Fair value gap, bullish structure | -0.67% over 21 days · t = -6.43 · n = 111,973 statistically distinguishable from its control group |
| 2026-06-30 | Fair value gap, bullish structure | -0.67% over 21 days · t = -6.43 · n = 111,973 statistically distinguishable from its control group |
| 2026-06-11 | Equal lows taken out structure | -0.64% over 21 days · t = -4.75 · n = 55,661 statistically distinguishable from its control group |
| 2026-06-02 | Fair value gap, bearish structure | -0.45% over 21 days · t = -3.29 · n = 108,591 statistically distinguishable from its control group |
| 2026-05-21 | Fair value gap, bullish structure | -0.67% over 21 days · t = -6.43 · n = 111,973 statistically distinguishable from its control group |
Excess return against a matched control group, on a point-in-time universe that includes delisted companies. Most families do not survive that. How the measurement works →
Insider transactions (Form 4)
| date | insider | what | shares | price | value |
|---|---|---|---|---|---|
| 2026-04-28 | Cormorant Global Healthcare Master Fund, LP | Open-market sale | 109.3K | 89.50 | 9.8M |
| 2026-04-28 | Chen Bihua | Open-market sale | 109.3K | 89.50 | 9.8M |
| 2026-04-28 | Cormorant Asset Management, LP | Open-market sale | 109.3K | 89.50 | 9.8M |
| 2024-11-04 | Cormorant Asset Management, LP | Open-market purchase | 184.3K | 21.70 | 4.0M |
| 2024-11-04 | Chen Bihua | Open-market purchase | 184.3K | 21.70 | 4.0M |
| 2024-10-16 | Chen Bihua | Open-market purchase | 39.7K | 23.22 | 922.8K |
| 2024-10-16 | Cormorant Asset Management, LP | Open-market purchase | 39.7K | 23.22 | 922.8K |
| 2024-10-16 | Cormorant Global Healthcare Master Fund, LP | Open-market purchase | 39.7K | 23.22 | 922.8K |
| 2024-10-16 | Cormorant Asset Management, LP | Open-market purchase | 7.2K | 24.03 | 171.8K |
| 2024-10-16 | Chen Bihua | Open-market purchase | 7.2K | 24.03 | 171.8K |
Open-market purchases (code P) are the informative ones. Grants, option exercises and tax withholding are compensation mechanics, not decisions. How to read a Form 4 →
Largest institutional holders
| manager | value | shares |
|---|---|---|
| JANUS HENDERSON GROUP PLC | 93.5M | 1.3M |
| Cormorant Asset Management, LP | 77.3M | 1.1M |
| BlackRock, Inc. | 45.4M | 621.9K |
| Vivo Capital, LLC | 40.7M | 557.2K |
| BRAIDWELL LP | 39.4M | 539.7K |
| ADAGE CAPITAL PARTNERS GP, L.L.C. | 36.2M | 495.7K |
| Vestal Point Capital, LP | 35.9M | 492.3K |
| Driehaus Capital Management LLC | 31.6M | 432.5K |
| PERCEPTIVE ADVISORS LLC | 27.5M | 377.5K |
| Balyasny Asset Management L.P. | 21.7M | 297.2K |
13F positions as of 2026-03-31, filed up to 45 days after quarter end. Long-only US equity — shorts and derivatives never appear. What 13F does and does not show →
Latest SEC filings
| form | filed | period | |
|---|---|---|---|
| 6-K | 2026-08-17 | 2026-06-30 | on EDGAR ↗ |
| SCHEDULE 13G/A | 2026-08-14 | — | on EDGAR ↗ |
| S-8 | 2026-08-13 | — | on EDGAR ↗ |
| SCHEDULE 13G/A | 2026-08-12 | — | on EDGAR ↗ |
| SCHEDULE 13D/A | 2026-07-02 | — | on EDGAR ↗ |
| 6-K | 2026-06-03 | 2026-03-31 | on EDGAR ↗ |
| 6-K | 2026-06-02 | 2026-01-20 | on EDGAR ↗ |
| 6-K | 2026-05-28 | 2026-05-26 | on EDGAR ↗ |
Short selling
This is off-exchange short volume, not short interest: it is flow, not position, and 40–50% is normal because market makers short to fill your buy. Why that number misleads →
Recent headlines
- BRIGHT MINDS BIOSCIENCES INC. (DRUG) filed form 6-K · 2026-08-17 · SEC EDGAR
Ask the AI about DRUG
The assistant reads every block on this page — price history, filings, insider transactions, institutional positions, short volume, macro and the measured base rates — and says what it implies, quoting the number behind each claim and declaring what it does not have.
Everything on this page is live in the terminal.
Charts, filings, insider flow and the AI — open without an account.
Free plan for good. Pro is $69.99/mo, or $4.99 for a 7-day trial. See the plans →